Drug intelligence / Profile preview

GO-R170

Development stage: Preclinical
Lead developer: GO Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GO-R170 is an antibody-based therapeutic candidate developed by GO Therapeutics, currently in early-stage development for the treatment of multiple solid tumors. The drug utilizes GO Therapeutics' proprietary platform to target tumor-specific truncated O-glycans, specifically the Tn (GalNAc-alpha-Ser/Thr) and STn (Sialyl-Tn) antigens. These glycan structures are truncated versions of normal O-glycans and are expressed almost exclusively on cancer cells due to altered glycosylation pathways, making them highly specific "super-clean" tumor antigens. GO-R170 is designed to selectively bind these antigens on the tumor cell surface to mediate anti-tumor activity while sparing healthy tissues.

Targets

TA-MUC1 (Tumor-associated MUC1)

Beyond the preview

Go deeper on GO-R170.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-R170.

Explore the full profile